No gross overdoses in clinical practice have been reported. Coronary vasospasm was observed after intravenous administration of sumatriptan injection [see CONTRAINDICATIONS]. Overdoses would be expected from animal data (dogs at 0.1 g/kg, rats at 2 g/kg) to possibly cause convulsions, tremor, inactivity, erythema of the extremities, reduced respiratory rate, cyanosis, ataxia, mydriasis, injection site reactions (desquamation, hair loss, and scab formation), and paralysis.

The apparent elimination half-life of sumatriptan after ZECUITY administration is about 3 hours [see CLINICAL PHARMACOLOGY], and therefore monitoring of patients after overdose with ZECUITY should continue for at least 15 hours or while symptoms or signs persist.

It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan.

ZECUITY is contraindicated in patients with:

• Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see WARNINGS AND PRECAUTIONS].
• Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see WARNINGS AND PRECAUTIONS].
• History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see WARNINGS AND PRECAUTIONS].
• Peripheral vascular disease [see WARNINGS AND PRECAUTIONS].
• Ischemic bowel disease [see WARNINGS AND PRECAUTIONS].
• Uncontrolled hypertension [see WARNINGS AND PRECAUTIONS].
• Recent (i.e., within 24 hours) use of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptaminei (5-HT₁) agonist [see DRUG INTERACTIONS].
• Concurrent administration of an MAO-A inhibitor or recent (within 2 weeks) use of a MAO-A inhibitor [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY].
• Known hypersensitivity to sumatriptan or components of ZECUITY [see WARNINGS AND PRECAUTIONS].
• Severe hepatic impairment [see CLINICAL PHARMACOLOGY].
• Allergic contact dermatitis to ZECUITY [see WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 1/31/2013
This monograph has been modified to include the generic and brand name in many instances.